Fol­low­ing con­tro­ver­sy, new Bio­gen di­rec­tor Su­san Langer won fewest votes from share­hold­ers

Af­ter her con­tro­ver­sial nom­i­na­tion by Alex Den­ner to Bio­gen’s board, Su­san Langer was elect­ed this week with few­er votes than any oth­er mem­ber of the eight-per­son group.

Ac­cord­ing to an SEC fil­ing, 64 mil­lion shares were vot­ed in sup­port of her join­ing the board, with 46.6 mil­lion against and 8.5 mil­lion ab­sten­tions.

Langer is a biotech ex­ec­u­tive and for­mer Bio­gen cor­po­rate de­vel­op­ment leader who is al­so said to be the ro­man­tic part­ner of Den­ner, the long­time Bio­gen di­rec­tor who, ac­cord­ing to the com­pa­ny, pro­posed her as his re­place­ment. Her ré­sumé in­cludes stints across Bio­gen, a life sci­ences VC firm with her broth­er and work at var­i­ous oth­er biotechs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER